Stephanie Njau1, Shantanu H Joshi1, Randall Espinoza1, Amber M Leaver1, Megha Vasavada1, Antonio Marquina1, Roger P Woods1, Katherine L Narr1. 1. From the Ahmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California, Los Angeles, Calif., USA (Njau, Joshi, Leaver, Vasavada, Woods, Narr); the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Calif., USA (Espinoza, Woods, Narr); and the Department of Mathematics, University of Valencia, Valencia, Spain (Marquina).
Abstract
BACKGROUND: Electroconvulsive therapy (ECT) is a highly effective brain stimulation treatment for severe depression. Identifying neurochemical changes linked with ECT may point to biomarkers and predictors of successful treatment response. METHODS: We used proton magnetic resonance spectroscopy (1H-MRS) to measure longitudinal changes in glutamate/glutamine (Glx), creatine (Cre), choline (Cho) and N-acetylaspartate (NAA) in the dorsal (dACC) and subgenual anterior cingulate cortex (sgACC) and bilateral hippocampus in patients receiving ECT scanned at baseline, after the second ECT session and after the ECT treatment series. Patients were compared with demographically similar controls at baseline. Controls were assessed twice to establish normative values and variance. RESULTS: We included 50 patients (mean age 43.78 ± 14 yr) and 33 controls (mean age 39.33 ± 12 yr) in our study. Patients underwent a mean of 9 ± 4.1 sessions of ECT. At baseline, patients showed reduced Glx in the sgACC, reduced NAA in the left hippocampus and increased Glx in the left hippocampus relative to controls. ECT was associated with significant increases in Cre in the dACC and sgACC and decreases in NAA in the dACC and right hippocampus. Lower NAA levels in the dACC at baseline predicted reductions in depressive symptoms. Both ECT and symptom improvement were associated with decreased Glx in the left hippocampus and increased Glx in the sgACC. LIMITATIONS: Attrition and clinical heterogeneity may have masked more subtle findings. CONCLUSION: ECT elicits robust effects on brain chemistry, impacting Cre, NAA and Glx, which suggests restorative and neurotrophic processes. Differential effects of Glx in the sgACC and hippocampus, which approach control values with treatment, may reflect previously implicated underactive cortical and overactive subcortical limbic circuitry in patients with major depression. NAA levels at baseline are predictive of therapeutic outcome and could inform future treatment strategies.
BACKGROUND: Electroconvulsive therapy (ECT) is a highly effective brain stimulation treatment for severe depression. Identifying neurochemical changes linked with ECT may point to biomarkers and predictors of successful treatment response. METHODS: We used proton magnetic resonance spectroscopy (1H-MRS) to measure longitudinal changes in glutamate/glutamine (Glx), creatine (Cre), choline (Cho) and N-acetylaspartate (NAA) in the dorsal (dACC) and subgenual anterior cingulate cortex (sgACC) and bilateral hippocampus in patients receiving ECT scanned at baseline, after the second ECT session and after the ECT treatment series. Patients were compared with demographically similar controls at baseline. Controls were assessed twice to establish normative values and variance. RESULTS: We included 50 patients (mean age 43.78 ± 14 yr) and 33 controls (mean age 39.33 ± 12 yr) in our study. Patients underwent a mean of 9 ± 4.1 sessions of ECT. At baseline, patients showed reduced Glx in the sgACC, reduced NAA in the left hippocampus and increased Glx in the left hippocampus relative to controls. ECT was associated with significant increases in Cre in the dACC and sgACC and decreases in NAA in the dACC and right hippocampus. Lower NAA levels in the dACC at baseline predicted reductions in depressive symptoms. Both ECT and symptom improvement were associated with decreased Glx in the left hippocampus and increased Glx in the sgACC. LIMITATIONS: Attrition and clinical heterogeneity may have masked more subtle findings. CONCLUSION: ECT elicits robust effects on brain chemistry, impacting Cre, NAA and Glx, which suggests restorative and neurotrophic processes. Differential effects of Glx in the sgACC and hippocampus, which approach control values with treatment, may reflect previously implicated underactive cortical and overactive subcortical limbic circuitry in patients with major depression. NAA levels at baseline are predictive of therapeutic outcome and could inform future treatment strategies.
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: Aaron T Hess; M Dylan Tisdall; Ovidiu C Andronesi; Ernesta M Meintjes; André J W van der Kouwe Journal: Magn Reson Med Date: 2011-03-04 Impact factor: 4.668
Authors: D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari Journal: Neuroimage Date: 2004-05 Impact factor: 6.556
Authors: Wolfgang Block; Frank Träber; Olrik von Widdern; Martin Metten; Hans Schild; Wolfgang Maier; Astrid Zobel; Frank Jessen Journal: Int J Neuropsychopharmacol Date: 2008-10-10 Impact factor: 5.176
Authors: M Dylan Tisdall; Aaron T Hess; Martin Reuter; Ernesta M Meintjes; Bruce Fischl; André J W van der Kouwe Journal: Magn Reson Med Date: 2011-12-28 Impact factor: 4.668
Authors: Sarah H Lisanby; Shawn M McClintock; George Alexopoulos; Samuel H Bailine; Elisabeth Bernhardt; Mimi C Briggs; C Munro Cullum; Zhi-De Deng; Mary Dooley; Emma T Geduldig; Robert M Greenberg; Mustafa M Husain; Styliani Kaliora; Rebecca G Knapp; Vassilios Latoussakis; Lauren S Liebman; William V McCall; Martina Mueller; Georgios Petrides; Joan Prudic; Peter B Rosenquist; Matthew V Rudorfer; Shirlene Sampson; Abeba A Teklehaimanot; Kristen G Tobias; Richard D Weiner; Robert C Young; Charles H Kellner Journal: Am J Geriatr Psychiatry Date: 2019-10-12 Impact factor: 4.105
Authors: Brian P Brennan; Roee Admon; Chris Perriello; Erin M LaFlamme; Alison J Athey; Diego A Pizzagalli; James I Hudson; Harrison G Pope; J Eric Jensen Journal: Psychiatry Res Neuroimaging Date: 2017-09-01 Impact factor: 2.376
Authors: Amber M Leaver; Megha Vasavada; Shantanu H Joshi; Benjamin Wade; Roger P Woods; Randall Espinoza; Katherine L Narr Journal: Biol Psychiatry Date: 2018-10-05 Impact factor: 12.810
Authors: M Cano; I Martínez-Zalacaín; Á Bernabéu-Sanz; O Contreras-Rodríguez; R Hernández-Ribas; E Via; A de Arriba-Arnau; V Gálvez; M Urretavizcaya; J Pujol; J M Menchón; N Cardoner; C Soriano-Mas Journal: Transl Psychiatry Date: 2017-02-07 Impact factor: 6.222
Authors: Amber M Leaver; Benjamin Wade; Megha Vasavada; Gerhard Hellemann; Shantanu H Joshi; Randall Espinoza; Katherine L Narr Journal: Front Psychiatry Date: 2018-03-21 Impact factor: 5.435
Authors: Olga Therese Ousdal; Giulio E Brancati; Ute Kessler; Vera Erchinger; Anders M Dale; Christopher Abbott; Leif Oltedal Journal: Biol Psychiatry Date: 2021-05-31 Impact factor: 13.382